|

Administration of Vorolanib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Li-kun Chen1

Indications

  • Angiogenesis Inhibition in Oncology1
  • Third-line and Beyond Therapy1
  • Recurrent or Metastatic Lung Cancer1
  • Advanced Non Small Cell Lung Cancer (NSCLC)1
  • Lung Cancer1

Other1 trial

Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.